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THE OWNERSHIP AND PATENTING OF




On August 9, 2001, President George W. Bush announced
the administration's stem cell research policy-the National Insti-
tutes of Health (NIH) would only grant funds to research pro-
jects using pre-existing stem cell lines.' Embryonic stem cells are
totipotential. 2 They are undifferentiated cells capable of forming
into any type of cell in the human body.3 Scientists believe that
stem cells have two major uses, human reproductive cloning
and therapeutic cloning.4 Reproductive cloning ultimately re-
sults in producing an exact genetic replica of another human be-
ing.5 Therapeutic cloning aims to manipulate the stem cells to
grow into specific cells and organs for transplant to replace de-
fective ones.6 Simply stated, the blind will see again and the
crippled will walk again.
It will be decades before any meaningful inventions will re-
sult from stem cell research.7 For the 2002 fiscal year, the NIH
* Technical Editor, Santa Clara Law Review, Volume 43. J.D. candidate,
Santa Clara University School of Law; B.S., B.A., Seattle University.
1.See Michael D. Lemonick, Keeper of the Stem Cells, TIME, Aug. 27, 2001, at 57.
2.See Seth Shulman, The Morphing Patent Problem, TECH. REV., Nov. 1, 2001, at 33.
3. See id. ("[H]uman embryonic stem cells are undifferentiated cells taken
from fertilized embryos that can morph into virtually any of the more than 200 cell
types in the human body.").
4. Jennie James et al., One Step Too Far?, TIME INT'L, Dec. 10, 2001, at 61.
5. See id.
6. See id.
7. See Kerry Capell et al., Up for Grabs: A Golden Biotech Opportunity, Bus. WK.
INT'L EDITIONS, Sept. 10, 2001, at 20. Most biotechnology inventions result from re-
search that was federally funded. See id. The NIH research budget is $18.8 billion
and dwarfs that of other countries. Restrictions on the type of stem cells useable for
basic research will slow progress. See id. See also Jim Clark, Squandering Our Tech-
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budget totals $23 billion.8 The funding criteria under the budget
are: (a) the stem cells must have been derived from an embryo
that was created for reproductive purposes; (b) the embryo was
no longer needed for these purposes; (c) informed consent must
have been obtained for the donation of the embryo; and (d) no
financial inducements were provided for donation of the em-
bryo.9 Seventy-eight stem cell lines meet the President's crite-
ria.10 However, very few stem cell lines are mature enough to
conduct meaningful research right away.1" No one is sure how
embryonic stem cells can be developed into specific tissues.' 2
But ultimately these cells could hold the key to treatments for
Parkinson's disease, stroke, diabetes, and a range of other
deadly diseases. 13 In the future, scientists will develop inven-
tions making practical use of stem cells.
In the United States, Geron, a private company, has the li-
censing rights to seven stem cell lines.' 4 Recently the NIH, in
agreement with WiCell,15 has agreed to make available five stem
nological Future, N.Y. TIMES, Aug. 31, 2001, at A19 ("I believe our country risks being
thrown into a dark age of medical research .... It is futile to think that private
funding can make up what is being lost to laws driven by conservative politics.").
8. Press Release, National Institutes of Health, FY 2002 President's Budget
(Apr. 9, 2001), available at http://www4.od.nih.gov/officeofbudget/press2002.pdf.
9. See NATIONAL INSTITUTES OF HEALTH, EMBRYONIC STEM CELL REGISTRY,
available at http://escr.nih.gov (last updated Nov. 18, 2002) [hereinafter REGISTRY].
The registry of stem cell lines satisfying the President's criteria was announced on
August 9, 2001. See id.
10. See id.
11. See Sheryl G. Stolberg, U.S. Concedes Some Cell Lines Are Not Ready, N.Y.
TIMES, Sept. 6, 2001, at Al. Of the sixty plus lines that meet the President's criteria,
only twenty-four or twenty-five of them were ready for experimentation. See id.
Sweden's University of Goteburg has the world's largest cache of stem cell lines at
nineteen, but only three are ready for research use. See id. See also Karen Tumulty
& James Carney, Bush's Fuzzy Science, TIME, Sept. 10, 2001, at 35 ("[Goteburg's] re-
searchers had told Thompson... that only three had progressed beyond the earli-
est, most tentative stages. Goteborg fertility expert Lars Hamberger told the Wash-
ington Post that he and his colleagues thought the White House had either made a
'mistake' or had decided to 'stretch things' to suit its need for a larger number.");
Mike Pezzella, Who's Got the Stem Cells? NIH Says 10 Groups, BIOTECHNOLOGY
NEWSWATCH, Sept. 3, 2001, at 1 (commenting that even private researchers may
have difficulty finding mature stem cell lines and would have to use cell lines on
the NIH registry).
12. See Stolberg, supra note 11, at Al.
13. See id.
14. See REGISTRY, supra note 9.
15. WiCell is a subsidiary of Wisconsin Alumni Research Foundation
(WARSF), the University of Wisconsin's Intellectual Property arm, which owns the
patent to the process of procuring stem cell lines. See infra notes 136-49 and accom-
panying text.
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cell lines to NIH scientists at a relatively low cost.16 Other or-
ganizations with stem cell lines in the United States are CyThera,
Inc. with nine, the University of California with two, 17 and the
Wisconsin Alumni Research Foundation with five.18 Against
this backdrop of narrowing research parameters and a lucrative
market in developing therapies for replacing ailing or destroyed
tissue, addressing the ownership and intellectual property rights
of future inventions becomes increasingly important. This is es-
pecially true when these rights can be easily worth billions of
dollars and have the potential to benefit more than 128 million
Americans. 19
Currently, the regulatory regime in the United States is si-
lent as to whether human beings or human body parts are pat-
entable.20 United States law has been slow in recognizing prop-
16. Press Release, National Institutes of Health, National Institutes of Health
and WiCell Research Institute, Inc., Sign Stem Cell Research Agreement (Sept. 5,
2001), available at http:/ /www.nih.gov/news/pr/sep2001/od-05.htm [hereinafter
Agreement].
NIH will be able to access these cell lines to explore new avenues of re-
search in this emerging field of technology. In compliance with NIH
guidelines for the transfer of research materials, this agreement permits
NIH scientists to freely publish the results of their research. The NIH will
retain its ownership to any new intellectual property that might arise from
the conduct of its research in this area .... WiCell will retain commercial
rights to its materials and will receive a fee to cover its handling and dis-
tribution expenses in supplying these cell lines. Furthermore, WiCell has
agreed to make stem cell lines available for use by non-profit institutions
that receive grants from the NIH under the same terms and conditions as
those available to NIH scientists, provided those institutions enter into a
separate written agreement with WiCell.
Id.
17. The University of California, San Francisco, developed the two stem cell
lines. The two are being HSF-6, which is currently available, and HSF-1, which will
be available soon. Interested researchers can obtain the stem cell lines by remitting
$5,000 to "The Regents of the University of California." See University of Califor-
nia, San Francisco's Stem Cell Webpage, at http://escells.ucsf.edu/ (last updated
Sept. 26, 2002).
18. See Agreement, supra note 16. The University of California, San Francisco,
developed its two stem cell lines: HSF-6 and HSF-1. See University of California,
San Francisco, Information on University of California, San Francisco's Human Embry-
onic Stem Cell Lines, at http://escells.ucsf.edu/ (last updated Sept. 26, 2002). While
HSF-6 is currently available, HSF-1 is not. See id. Interested researchers can obtain
the stem cell lines by remitting $5,000 to "The Regents of the University of Califor-
nia." See id.
19. See AUDREY CHAPMAN ET AL., AM. ASS'N FOR THE ADVANCEMENT OF SCI.,
STEM CELL RESEARCH AND APPLICATIONS MONITORING THE FRONTIERS OF
BIOMEDICAL RESEARCH 4 (1999), available at
http://www.aaas.org/spp/sfrl/projects/stem/report.pdf.
20. See Diamond v. Chakrabarty, 447 U.S. 303 (1980) (raising the question
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erty rights in human biological materials. 21 Will the innovative
efforts of companies spending millions of dollars provide them
no financial benefit because ownership resides with the genetic
donor or because the inventions are not patentable? This com-
ment will not address the ethical or religious issues regarding
whether stem cell research should be permitted or patented.
Rather, it will explore (a) the relevant law and case precedent
addressing property rights in human biological materials; (b)
whether any inventions arising from stem cells are patentable
under current law and trends; and (c) whether patent law
should be modified to better accommodate stem cell research.
II. BACKGROUND
A. Ownership Interests
The issue of ownership is an important question in the area
of stem cell research in light of our nation's health expenditure
per annum. In 1970, Americans spent $73.2 billion on health
care; they spent $245.8 billion in 1980, $699.4 billion in 1990, and
$1.3 trillion in 2000.22 They will spend a projected $2.3 trillion in
2008.23 Over the last few years, the United States' health care
expenditure has been 13.1%-14.0% of our nation's gross domes-
tic product.24 That number is projected to be at 16.3% in 2008.25
Therefore, ownership issues in future technological inventions
represent significant financial interests.
There is no established law directly addressing one's prop-
whether human beings and body parts are patentable). The Court held that altered
living microbial organisms, not naturally occurring, qualify as "patentable subject
matter." See id. at 309. The patent was held valid and no cases since then have
dealt with either human beings or body parts. See id. at 318. The state of science
has not yet progressed to the point where genetic material can be isolated to manu-
facture specific body parts. See generally Ned Hettinger, Patenting Life: Biotechnology,
Intellectual Property, and Environmental Ethics, 22 B.C. ENVTL. AFF. L. REV. 267 (1995);
Neil Munro, An Interesting Disinterest in Cloning, 33 NAT'L J. SCI.& TECH. 36 (2001).
21. See Moore v. Regents of the Univ. of Cal., 51 Cal. 3d 120 (1990) (holding that
an individual no longer had a property interest in his excised spleen cells even
though his physician failed to provide proper informed consent by not disclosing
his medical interests).
22. See CENTER FOR MEDICARE AND MEDICAID SERVICES, NATIONAL HEALTH
CARE EXPENDITURE PROJECTIONS: 2001-2011, available at
http://cms.hhs.gov/statistics/nhe/projections-2001/proj2OOl.pdf (last visited
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erty rights in one's own biological materials. 26 Do individuals
have ownership rights in any invention derived from their own
stem cells? Several cases dealing with ownership interests in
human organic material shed some light on these questions.
First, in Moore v. Regents of the University of California, the
California Supreme Court held that a patient no longer had a
property interest in his own excised cells where the attending
physician removed the patient's spleen as a treatment for hairy
cell leukemia. 27 Moore visited the University of California, Los
Angeles (UCLA) Medical Center on October 5, 1976.28 He was
hospitalized and "extensive amounts of blood, bone marrow as-
pirate, and other bodily substances" were withdrawn, confirm-
ing that Moore had hairy cell leukemia.29 By this time, Dr.
Golde and the other physicians were aware that Moore's spleen
cells were unique and of commercial value. 30
After the operation, Golde made arrangements and con-
ducted research on Moore's spleen cells.31 Meanwhile, he had
Moore come to Los Angeles from Seattle periodically for exami-
nation during which Golde withdrew more samples of "blood,
blood serum, skin, bone marrow aspirate, and sperm."32 These
samples could have been taken in a medical laboratory in Seattle
and sent to Los Angeles but Golde advised Moore that "the pro-
cedures were to be performed only [at the UCLA Medical Cen-
ter] and only under [Golde's] direction." 33 Meanwhile, Golde
performed research on Moore's spleen cells and concealed it
from Moore. 34 Finally, in 1979, Golde established a cell line and
in 1981, applied for a patent that issued in 1984. 35 Golde then
entered into a licensing arrangement with Sandoz Pharamaceu-
ticals in which he was to be paid at least $330,000 over three
years in exchange for Sandoz's exclusive access to materials and
26. See generally Amy S. Cain, Property Rights in Human Biological Materials:
Studies in Species Reproduction and Biomedical Technology, 17 ARIZ. J. INT'L & COMP. L.
449 (2000) (arguing that if courts and laws would find a property interest in one's
own human biological materials, such would allay the fears that individuals have
regarding the development of genomic cloning techniques and methods).




31. See id. at 126.
32. Moore, 51 Cal. 3d at 120.
33. See id.
34. See id.
35. See id. at 127.
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research performed on the patented cell line.36 Golde also ac-
quired 75,000 shares of stock and became a paid consultant for
Sandoz. 37 The patent rights generated $15 million in revenue for
Sandoz and "an estimated three billion dollars worth of drugs
that followed from it."38
Upon realizing what Golde had done, Moore sued for an in-
terest in the commercial stake on the tort theory of conversion
and twelve other causes of action.39 The superior court sus-
tained the defendants' general demurrer.40 Moore appealed and
the Court of Appeals for the Second District reversed "holding
that the complaint did state a cause of action for conversion."
41
Defendants appealed, and the Supreme Court of California sub-
sequently reversed the decision of the court of appeals.42 The
Supreme Court of California held that Moore did state a cause of
action-Golde breached his fiduciary duty to Moore by failing to
disclose his economic interest in Moore's spleen.43 However, in
addressing a tort conversion theory, the court held that Moore
no longer had any property interest in his own excised cells un-
der the California Health and Safety Code.44 The Supreme Court
of California only addressed the very narrow question of owner-
36. See id.
37. Id. at 127-28.
38. See Symposium, Patent Rights and Licensing, 6 B.U.J. SCI. & TECH. L. 3 (2000).
Professor Michael Mauer, a faculty member at Boston University School of Law,
participated in the symposium and focused on biotech patent litigation history and
the motivation in patenting and commercializing biotech inventions. See id. See also
Christopher S. Pennisi, More on Moore: A Novel Strategy for Compensating the Human
Sources of Patentable Cell-Line Inventions Based on Existing Law, 11 FORDHAM INTELL.
PROP. MEDIA & ENT. L.J. 747 (2001) (arguing that ownership rights for individuals
can be arranged via contracts).
39. See Moore, 51 Cal. 3d at 128.
40. See id. The trial court sustained the general demurrer in favor of defendants
against Moore's conversion theory but did not decide on causes of action two
through thirteen. See id. at 128 n.5.
41. Id. at 128.
42. See id. at 125.
43. See id. at 128-29.
44. Moore, 51 Cal. 3d at 136-37.
Neither the Court of Appeal's opinion, the parties' briefs, nor our research
discloses a case holding that a person retains a sufficient interest in excised
cells to support a cause of action for conversion. We do not find this sur-
prising, since the laws governing such things as human tissues, trans-
plantable organs, blood, fetuses, pituitary glands, corneal tissue, and dead
bodies deal with human biological materials as objects sui generis, regulat-
ing their disposition to achieve policy goals rather than abandoning them
to the general law of personal property.
Id. at 137 (citations omitted).
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ship of human biological material under the tort theory of con-
version argued by Moore. 45
The Tennessee Supreme Court dealt with the issue of own-
ership rights in unused embryos in Davis v. Davis,46 a case of first
impression.47 The Davis family took part in a fertilization pro-
gram but did not sign a written agreement with instructions re-
garding the disposal of unused embryos should an unforeseen
circumstance arise.48 Mr. Davis eventually filed for divorce. 49
Although she was not pregnant at the time, Mrs. Davis compli-
cated the divorce proceedings because she wanted to make use
of the frozen embryos to impregnate herself after the divorce.50
Mr. Davis objected because "he preferred to leave the embryos
in their frozen state until he decided whether or not he wanted
to become a parent outside the bounds of marriage."5'
By the time the case made its way to the Tennessee Su-
preme Court, Mrs. Davis remarried and moved out of state.52
Although she no longer desired to use the embryos for herself,
Mrs. Davis wanted them to be donated to a childless couple.5 3
Mr. Davis still wanted the embryos discarded.5 4
The Tennessee Supreme Court ruled that Mr. Davis' interest
in avoiding fatherhood was greater than Mrs. Davis' interest in
donating the frozen embryos to a third party.S5 The court con-
cluded that the frozen embryos, strictly speaking, were neither a
person nor property, so it gave Mr. Davis a very narrow prop-
erty ownership interest allowing him to decide the matter of
disposition.56
45. See id. at 120.
46. 842 S.W.2d 588 (Tenn. 1992).
47. See id.
48. See id. at 589-90.
49. See id.
50. See id.
51. Davis, 842 S.W.2d at 589.
52. See id. at 590.
53. See id.
54. See id.
55. See id. at 604.
56. See id. at 597.
We conclude that preembryos are not, strictly speaking, either 'persons' orIproperty,' but occupy an interim category that entitles them to special re-
spect because of their potential for human life. It follows that any interest
that Mary Sue Davis and Junior Davis have in the preembryos in this case
is not a true property interest. However, they do have an interest in the
nature of ownership, to the extent that they have decision-making author-
ity concerning disposition of the preembryos, within the scope of policy
2003]
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Although property rights in human biological materials
have been narrowly-tailored,57 the history of patents and pat-
entable items must be explored in order to determine the possi-
ble patentability of human biological materials.
58
B. Patent Law
1. The Legal Development of the Patent Statute
The foundation of patent law is grounded in Article 1, Sec-
tion 8, Clause 8 of the United States Constitution, which reads in
full: "To promote the Progress of Science and useful Arts, by se-
curing for limited Times to Authors and Inventors the exclusive
Right to their respective Writings and Discoveries." 59 The Con-
stitution does not provide guidelines as to what is patentable.
60
Congress enacted the first patent in 1790.61 "It authorized
patents for 'any useful art, manufacture, engine, machine, or de-
vice, or any improvement therein not before known or used,'
provided a designated group of executive officers (the Secretary
of State, the Secretary of War, and the Attorney General) deter-
mined that the invention was 'sufficiently useful and impor-
tant."' 62 This act was replaced in 1793, lowering its impor-
tance. 63
The 1836 and 1870 Acts were a major overhaul of the patent
system: they created a patent office, introduced a system for ex-
amining patent applications, and introduced statutory bars pro-
hibiting the issuance of patents.64
a. The Plant Acts
The 1930 Plant Patent Act (PPA) offers protection to some
asexually reproduced plants.65 In 1970, Congress passed the
set by law.
Id.
57. See Moore v. Regents of the Univ. of Cal. 51 Cal. 3d 120, 120 (1990); Davis,
842 S.W.2d at 588.
58. See U.S. CONST. art. I, § 8, cl. 8; 35 U.S.C. §§ 101-376 (2001). See generally
DONALD CHISUM, CHISUM ON PATENTS (2001).
59. U.S. CONST. art. I, § 8, cl. 8.
60. See id.
61. See CHISUM, supra note 58, § 2.
62. Id.
63. See id.
64. See id. § 3.
65. See 35 U.S.C. § 161 (2001).
Whoever invents or discovers and asexually reproduces any distinct and
[Vol. 43604
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Plant Variety Protection Act (PVPA) authorizing protection for
certain sexually reproduced plants but excluded bacteria from
its protection.66
b. The 1952 Statute
The modern patent statute is based on the passage of the
1952 Act.67 "To a large extent, the 1952 Act rearranged existing
statutory provisions and stated in statutory form matters previ-
ously recognized only in court decisions and Patent Office prac-
tice." 68 As determined by that Act, eligible subject matter for the
issuance of a utility patent requires that the invention fall within
one of the following categories: (a) new and useful process; (b)
composition of matter; (c) machine; or (d) product of manufac-
ture.69 Additionally, in order for an invention to be patentable it
must also be novel, useful, and non-obvious.70
i. Novelty
The standard for determining novelty of an invention is
"anticipation." 71 Anticipation relates to novelty because if a ref-
erence pre-dates the invention that contains the claims of the in-
vention, then it is not novel but anticipated. 72 A claim in the in-
vention is anticipated and, therefore, not novel if there exists a
single prior source that contains all the essential elements of the
claim.73 The classic test of anticipation is "[that] which will in-
fringe, if later, will anticipate, if earlier." 74 One's own actions
can even serve as a bar under 35 U.S.C. section 102. 75 The public
new variety of plant, including cultivated sports, mutants, hybrids, and
newly found seedlings, other than a tuber propagated plant or a plant
found in an uncultivated state, may obtain a patent therefore, subject to
the conditions and requirements of this title.
Id.
66. See 7 U.S.C. §§ 2321-2583 (2001).
67. See 35 U.S.C. §§ 1-376 (2001).
68. See CHISUM, supra note 58, § 6.
69. See 35 U.S.C. § 101 (2001) (specifying eligible subject matter as patentable).
70. See id. (requiring inventions be useful); id. § 102 (setting out the need for an
invention to be novel); id. § 103 (requiring the subject matter to be non-obvious in
order to be patentable). See also CHISUM, supra note 58, § 4.01 ("Utility, long a re-
quirement to obtain a patent in American law, means that an invention must per-
form some function of positive benefit to society.").




75. See 35 U.S.C. § 102 (2001).
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policy
is to require inventors to assert with due diligence their right
to a patent through the filing and prosecution of a patent ap-
plication. Lack of diligence by the inventor delays the time
when the valuable invention is disclosed to the public
through a published patent and delays the time when the in-
vention will be free of the statutory period of monopoly.76
Thus, if the invention is described in a printed publication, in
public use, or on sale, and the patent application is not filed
within one year of such events occurring, then the inventor will
not be entitled to a patent.77
ii. Utility
Under 35 U.S.C. section 101, an invention needs to be useful
in order to secure patent protection. 78 The standard for meeting
utility is not a stringent one.79 "[The invention] must be more
than 'a mere curiosity, a scientific process exciting wonder yet
not producing physical results, or [a] frivolous or trifling article
or operation not aiding in the progress nor increasing the pos-
session of the human race. '"' 80
iii. Non-obviousness
Under 35 U.S.C. § 103, an invention is non-obvious if it
would not be obvious to a person having ordinary skill in the
art.81 Unlike the novelty criterion, which must be determined by
looking at only a single prior source, examining non-obviousness
allows one to look at more than one source. 82
76. See CHISUM, supra note 58, § 6.01.
77. See 35 U.S.C. § 102 (2001).
78. See id. § 101 (requiring inventions be useful).
79. See CHISUM, supra note 58, § 4.02.
80. Id. (quoting 1 W. ROBINSON, TREATISE ON THE LAW OF PATENTS FOR USEFUL
INVENTIONS 463 (n.p. 1890)).
81. See 35 U.S.C. § 103 (2001).
A patent may not be obtained though the invention is not identically dis-
closed or described as set forth in section 102 of this title, if the differences
between the subject matter sought to be patented and the prior art are
such that the subject matter as a whole would have been obvious at the
time the invention was made to a person having ordinary skill in the art to
which said subject matter pertains. Patentability shall not be negatived by
the manner in which the invention was made.
Id.
82. See CHISUM, supra note 58, § 5.03.
[Vol. 43
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iv. The Written Description Requirement
Under 35 U.S.C. § 112, a patent application must contain an
adequate written description of the invention, definite claims,
and must disclose the best mode of making the invention as con-
templated by the inventor at the time of the filing of the applica-
tion.83 The public policy reason for these requirements is to pro-
vide an inventor the incentive to disclose enough information to
repeat the invention in exchange for a monopoly for a limited
time,8 4 thereby promoting the progression of the arts while also
serving as a flag to stake the inventor's claim.85
2. Cases Defining Eligible Subject Matter
A case having far-reaching effects regarding whether living
organisms could be patented is Diamond v. Chakrabarty.8 6 Prior
to Chakrabarty, living organisms (singular or multi-cellular) were
not patentable material because they were considered to be
products of nature rather than inventive discoveries.8 7 How-
ever, post-Chakrabarty, the stage was set for a showdown as to
whether human subject matter could be patented.88
In Chakrabarty, the invention was a genetically engineered
multi-cellular bacterium, which the inventors claimed was capa-
ble of breaking down oil and thus held significant value in the
treatment of oil spills.8 9 The original patent application sought
protection for both the process of producing the bacterium and
the bacterium itself.90 However, the claim to the bacterium was
83. See 35 U.S.C. § 112 (2001).
The specification shall contain a written description of the invention, and
of the manner and process of making and using it, in such full, clear, con-
cise, and exact terms as to enable any person skilled in the art to which it
pertains, or with which it is most nearly connected, to make and use the
same, and shall set forth the best mode contemplated by the inventor of
carrying out his invention.
Id.
84. See CHISUM, supra note 58, § 11.03 ("The 1994 Uruguay Round Agreements
Act altered the manner in which a patent's term is measured. Under pre-1995 law,
patents extended for 17 years from their issue date. The Act establishes a 20-year
term measured from the earliest-referenced priority application filing date.").
85. See DONALD CHISUM ET AL., PRINCIPLES OF PATENT LAW 3 (Robert C. Clark
et al. eds., 2d ed. 2001).
86. 447 U.S. 303 (1980) (deciding that non-natural organisms are eligible subject
matter for patents).
87. See id. at 314.
88. See id. at 303.
89. See id. at 305.
90. Id.
20031
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disallowed by the Board of Patent Appeals and Interferences.91
The Court of Customs and Patent Appeals reversed, holding
that "the fact that microorganisms ... are alive.., is without le-
gal significance." 92 The U.S. Supreme Court took the case on
appeal and addressed the issue whether the respondent's micro-
organism constituted a 'manufacture' or 'composition of matter'
within the meaning of the statute." 93 The Court reiterated that
naturally-occurring phenomena are not eligible subject matter.94
The government argued that living matter is not eligible
subject matter under 35 U.S.C. § 101. 95 The government pointed
to the fact that Congress' passage of the PPA and the PVPA
showed congressional intent to take living matter outside the
scope of § 101 protection.96 The Court dismissed this argument,
reasoning that prior to 1930 it was believed that the patent stat-
ute removed plants from its protection because of the belief that
artificially produced plants were products of nature and the dif-
ficulty of fulfilling the written description.97 Congress thus en-
acted the plant statutes to address those concerns. 98
The government's second argument was that unless Con-
gress explicitly authorized organisms as patentable subject mat-
ter there was no protection for the microorganism. 99 When § 101
was enacted genetic engineering was not yet in existence and
therefore not contemplated by Congress.100 The Court soundly
rejected this second argument stating, "[i]t is, of course, correct
that Congress, not the courts, must define the limits of pat-
entability; but it is equally true that once Congress has spoken it
is 'the province and duty of the judicial department to say what
the law is."' 10 1 The Court further elaborated that Congress had
91. Id. at 306.
92. Chakrabarty, 447 U.S. at 306 (citations omitted).
93. Id. at 307.
94. See id. at 309.
The laws of nature, physical phenomena, and abstract ideas have been
held not patentable .... Thus, a new mineral discovered in the earth or a
new plant found in the wild is not patentable subject matter. Likewise,
Einstein could not patent his celebrated law that E=mc 2; nor could Newton
have patented the law of gravity.
Id.
95. See id. at 310.
96. See id. at 310-12.
97. Chakrabarty, 447 U.S. at 310-12.
98. See id.
99. See id. at 314.
100. See id.
101. Id. at 315 (quoting Marbury v. Madison, 5 U.S. 137, 177 (1803)).
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defined what constituted patentable subject matter and that it is
within the Court's power to interpret what constitutes pat-
entable subject matter within the framework provided by Con-
gress.' 02 The Court rejected both of the government's arguments
when it decided that the microorganism constituted eligible sub-
ject matter under § 101.103 The Court reasoned that the bacte-
rium as a composition of matter or manufacture was "non-
naturally occurring.., a product of human ingenuity" and not a
natural phenomenon. 104 The bacterium was declared eligible
subject matter. 05 "[Chakrabarty's] discovery is not nature's
handiwork, but his own; accordingly it is patentable subject mat-
ter under § 101."106 This ruling launched the ever-increasing
likelihood that human organic matter may be held patentable.107
a. Relevant Cases Subsequent to Chakarabarty
In 2001, the Supreme Court decided a case involving geneti-
cally altered plants - J.E.M. AG Supply v. Pioneer Hi-Bred Inter-
national, Inc. 08 The issue was whether a utility patent could be
issued for plants or whether the PPA or the PVPA excludes an
inventor from federal statutory protection. 109 The Court held
that Pioneer could obtain a utility patent.110 The underlying in-
vention involved hybrid corn plant seeds for which Pioneer
owned the patents. 1' The resulting corn plants were "character-
ized by superior yield for maturity, excellent seedling vigor,
very good roots and stalks, and exceptional stay green."1 2
102. See id.
103. Chakrabarty, 447 U.S. at 309-10.
104. See id. at 309-10.
105. See id.
106. Id. at 310.
107. See Alison Abbott, A Post-Genomic Challenge: Learning to Read Patterns of Pro-
tein Synthesis, NATURE, Dec. 16, 1999, at 715-16, available at
http://www.forum.mpg.de/rueckblick/20020627/docs/nature-proteonics.pdf
[hereinafter Post-Genomic Challenge]. The Chakrabarty ruling affirmed the decision of
In re Application of Bergy. See Chakrabarty, 447 U.S. at 303. In a matter of first im-
pression, the United States Court of Customs and Patent Appeals dealt with a mi-
croorganism that produces lincomycin, an antibiotic. See id. Specifically, the Court
of Customs and Patent Appeals faced the question of "whether the uncontroverted
fact that the biologically pure culture, as claimed, is alive removes it from the cate-
gories of inventions enumerated in § 101." Id. (internal quotations omitted). They
answered in the negative. See id.
108. 534 U.S. 124 (2001).
109. See id. at 127.
110. See id.
111. See id.
112. Id. at 128 (referring to U.S. Patent No. 5,491,295, cols. 2-3).
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However, seeds produced by the hybrid plants did not consis-
tently yield the same characteristics as the parent, causing indi-
viduals desiring to grow more plants to purchase new seeds.113
Pioneer licensed its hybrid seeds to purchasers with the re-
striction that they could only use them for the production or for-
aging of plants, and prohibited the use of seeds or progeny re-
sulting from the plants of Pioneer's hybrid seeds.1 14 J.E.M.,
doing business as "Farm Advantage," purchased the hybrid
seeds from Pioneer with the limited license labels visibly dis-
played.115 Farm Advantage never had a license from Pioneer to
resell the hybrid corn products, yet they resold the corn product
to third-party purchasers. 116 Pioneer brought suit against Farm
Advantage for infringement of its patents. 117 As a defense, Farm
Advantage argued that the PPA, 35 U.S.C. § 161, and the PVPA,
7 U.S.C. § 2321, provided exclusive statutory protection for plant
life; therefore Pioneer's utility patents were invalid since they
were outside the scope of 35 U.S.C. § 101. 118
The district court granted summary judgment in favor of
Pioneer based on the Chakarabarty Court's broad construction of
35 U.S.C. § 101 and because the PPA and PPVA failed to remove
plants as subject matter considered under § 101.119 The Federal
Circuit Court affirmed 120 and the Supreme Court agreed, hold-
ing that newly developed plant breeds are within the scope of
patentable subject matter under § 101.121





118. Id. at 129.
119. J.E.M. AG Supply, 534 U.S. at 129.
Relying on this Court's broad construction of § 101 in Diamond v.
Chakarabarty, the District Court held that the subject matter covered by §
101 clearly includes plant life .... It further concluded that in enacting the
PPA and the PVPA Congress neither expressly nor implicitly removed
plants from § 101's subject matter. In particular, the District Court noted
that Congress did not implicitly repeal § 101 by passing the more specific




121. See id. at 145-46.
[W]e hold that newly developed plant breeds fall within the terms of §
101, and that neither the PPA nor the PVPA limits the scope of § 101's cov-
erage. As in Chakrabarty, we decline to narrow the reach of § 101 where
Congress has given us no indication that it intends this result. Accord-
[Vol. 43610
2003] STEM CELL RESEARCH & PATENTS
C. The State of the Science
1. Stem Cell Research
Stem cell research falls into two categories: human repro-
ductive cloning and therapeutic cloning.122 Human reproduc-
tive cloning involves the cloning of entire human beings. 123 On
the other hand, therapeutic cloning aims to manipulate stem
cells to grow into specific cells and organs to replace defective
ones.124 The fruits of this research will take time because neither
microarray technology125 nor any other equally effective method
ingly, we affirm the judgment of the Court of Appeals.
Id.
122. See James et al., supra note 4.
123. See id.
124. See id. This comment addresses only stem cell research for therapeutic pur-
poses.
125. A DNA Microarray is an analytical system for rapid genetic analysis that
typically involves six steps: (1) design of a specific probe; (2) fabrication onto a
thumb-nail sized glass wafer spotted with thousands of DNA strands; (3) prepara-
tion of a fluorescently tagged target sample; (4) assay; (5) read out; and (6) bioin-
formatics analysis. The DNA Microarray chip genesis process is somewhat analo-
gous to the production of a microchip. See Alexandra Stikeman, Biomedicine: Over
the Next Decade, Personally Tailored Drugs and Diagnostic Technologies Could Cure What
Ails You; The State of Innovation, TECHNOLOGY REVIEW, Jun. 1, 2002, at 58; Hisham
Hamadeh & Cynthia Afshari, Gene Chips and Functional Genomics, AM. SCIENTIST,
Nov. 1, 2000, at 508.
A DNA chip is made using a glass microscope slide, 7.62 centimeters by
2.54 centimeters and about 1.2 millimeters thick. Samples of DNA, in the
form of spots, are "printed" on the slide, using a procedure similar to the
one used to print computer chips. The DNA spots adhere to the slide, each
spot being a cloned DNA sequence that represents a gene. The DNA mole-
cules that make up the spots include either fully sequenced genes of
known function, or collections of partially sequenced, unknown genes.
Chip manufacturing- printing or spotting - is done with a machine called
an arrayer. Most arrayers are still custom-built instruments featuring a
high-speed robotic arm fitted with a number of pins. The arm is controlled
by software that allows the user to place genes in select areas and configu-
rations on the glass slide to generate a cDNA microarray chip. The pins re-
semble the tips of quill pens. By capillary action, each pin draws up a
small amount of a solution containing the DNA for a single gene and de-
posits it in a precise location on a glass slide. Since the arm holds many
such pins, many genes are deposited on the slide at a time. Computers
keep track of the location of each gene on the gene chip.
The arrayer is housed in a clean chamber where temperature and humid-
ity are monitored and maintained constant so as to produce consistent and
evenly sized spots. In some configurations it is possible to print up to
50,000 genes on one chip, and efforts are underway to increase that num-
ber as demand grows. The spotted genes/DNA are linked to the surface of
the glass slide by either covalent bonds or charge interactions.
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has been adopted in proteomics.126 Microarray technology al-
lows thousands of transcripts from a gene to be sequenced in a
single afternoon.127 Traditional methods of protein separation
are relatively slow and limiting. 28 Once separated, the protein
sequence is identified.129
The structure of protein is by far more complex than that of
deoxyribonucleic acid (DNA).130 While DNA is comprised of
four basic components (adenine, cytosine, guanine, and
thymine) in a double helical structure, 131 proteins are "highly
complicated beasts that fold up into intricate and often unpre-
dictable shapes. They are built from 20 building blocks, called
amino acids .... 132 Facing a more complicated structure than
126. See Alison Abbott, How to Spot a Protein in a Crowd?, NATURE, Dec. 16, 1999,
at 716, available at http://www.forum.mpg.de/rueckblick/20020627/
docs/nature-proteomics.pdf [hereinafter Spotting Protein]. Proteomics seeks to dis-
cover how proteins interact with other biomolecules and to discover the mecha-
nisms of proteins. See id. The traditional method of studying proteins is a two
stage process: (1) separating the proteins from a sample and (2) identifying the pro-
tein. See id. The application of microarray technology, like it did in the sequencing
of the genome, should dramatically speed up this process. See id.
127. See Hamadeh & Afshari, supra note 125, at 508.
Patrick Brown and colleagues at Stanford University developed a new
technology adapted from the microchips used by the computer industry.
The resulting DNA microarrays-the so-called gene chips-are indeed po-
tent investigative tools, where the status of thousands of genes from any
biological origin can be monitored simultaneously for changes in level of
gene expression. The difference between the old and new methods is
striking. Traditional assays measure RNA transcripts from one gene at a
time over a three-day period. Gene chips can measure transcripts from
thousands of genes in a single afternoon.
Id. at 509.
128. See Alison Abbott, Proteomics, Transcriptomics: Mhat's in a Name?, NATURE,
Dec. 16, 1999, at 715, available at
http://www.forum.mpg.de/rueckblick/20020627/docs/nature-proteomics.pdf
[hereinafter Proteomics]. Two dimensional gel electrophoresis is still the best
method of protein separation for sequence determination, but it is not without lim-
its. See Post-Genomic Challenge, supra note 107. "There is a limit to how many pro-
teins a single gel can separate, and the sensitivity is still not adequate to detect pro-
teins appearing at vary low levels. Some classes of protein.., will not run on 2D
gels." Id. at 716.
129. See Spotting Protein, supra note 126. Once a protein is separated it is di-
gested by proteases which fragmentize the protein. See id. Sequencing is generally
performed using mass spectroscopy. See id.
130. See Ellen Licking et al., Beyond the Genome: Biotech's Next Holy Grail, Bus.
WK., Apr. 10, 2000, at 136 ("Compared with proteins, DNA molecules are simple.").
131. See Keith Devlin, Round the Twist, NEW SCIENTIST, Nov. 10, 2001, at 40
("DNA isn't like an ordinary rope, where you can join two ends at any orientation.
Its structure, a double helix, means the ends cannot be connected unless they match
up in exactly the right way.").
132. Licking et al., supra note 130.
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DNA with slower analytical tools, the industry is in the process
of developing more advanced technology to identify and sepa-
rate proteins.133 Thus, there seems to be a large degree of corre-
lation between the aims of therapeutic cloning (manipulating
stem cells to grow into very specific cells and organs) and pro-
teomics, which looks at the mechanisms that result in the spe-
cialization of cells and their maintenance.
While research is generally conducted for knowledge, it is
not mutually excluded from using the information for financial
gain. 34 Currently, there are patents to stem cells that might very
well shape the landscape. 135
2. The Thomson Patents
On December 1, 1998, the United States Patent and Trade-
mark Office (USPTO) issued patent number 5,843,780 (the '780
patent) to inventor James Thomson for his isolation of primate
embryonic stem cells.136 He assigned his invention to the Uni-
133. See id. ("At least seven biotechs are racing to develop new tools to mine the
proteome .... The tools include powerful instruments that can sequence thousands
of proteins simultaneously.").
134. Scientific information can be used to gain a better understanding of the way
things work, such as the human genome, and that information at the same time can
be used for commercial gain.
135. See Hamadeh & Afshari, supra note 125; Proteomics, supra note 128.
136. See U.S. Patent No. 5,843,780 (issued Dec. 1, 1998). The '780 patent reads in
pertinent part:
1. A purified preparation of primate embryonic stem cells which (i) is ca-
pable of proliferation in an in vitro culture for over one year, (ii) maintains
a karyotype in which all the chromosomes characteristic of the primate
species are present and not noticeably altered through prolonged culture,
(iii) maintains the potential to differentiate into derivatives of endoderm,
mesoderm, and ectoderm tissues throughout the culture, and (iv) will not
differentiate when cultured on a fibroblast feeder layer.
9. A method of isolating a primate embryonic stem cell line, comprising
the steps of:
(a) isolating a primate blastocyst;
(b) isolating cells from the inner cell mass of the blastocyst of (a);
(c) plating the inner cell mass cells on embryonic fibroblasts, wherein inner
cell mass-derived cells masses are formed;
(d) dissociating the mass into dissociated cells;
(e) replating the dissociated cells on embryonic feeder cells;
(f) selecting colonies with compact morphologies and cells with high nu-
cleus to cytoplasm ratios and prominent nucleoli; and
(g) culturing the cells of the selected colonies.
11. A cell line developed by the method of step 9.
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versity of Wisconsin's Intellectual Property arm, Wisconsin
Alumni Research Foundation (WARF),137 which also owns the
patent to the process of procuring the stem cell lines. 138 A pri-
vate company, Geron, funded the research and in return re-
ceived the exclusive licensing rights to six human cell types from
human stem cell lines falling within the protection of '780 patent
and one other patent.139
Since 1995, Geron has spent more than $48 million on stem
cell research and development. 40 In August 2001, WARF sued
Geron to prevent the company from exercising an option that
would give them the exclusive rights to eleven more stem cell
lines. 141 As a result, on January 9, 2002, Geron and WARF
reached a settlement agreement 42 in which Geron retained the
rights to develop three types of stem cells-blood cells, bone cells,
and cartilage cells-while giving up the rights to nerve, heart,
and pancreatic cells.143 WARF has made five of its stem cell lines
available for research at very low fees.144
On March 13, 2001, the USPTO issued patent number
6,200,806 (the '806 patent) to James Thomson. 45 This patent is
substantially similar to that of the '780 patent except where the
word "primate" was used, the term "human" was substituted in
the '806 patent.146 The remaining language is the same. 47
Some believe that the language of the '780 patent claims is
overly broad, making "virtually all other embryonic cell lines...
fall under [one of] the Thomson patent[s]."148 This allegation
137. See id.
138. See id. Claim eleven recites the method of producing the cell line of claim
nine. See id.
139. Telephone Interview with Andrew Cohn, Government and Public Affairs
Manager, Wisconsin Alumni Research Foundation (Jan. 18, 2002).
140. See Andrew Pollack, University Foundation Says Geron May Lose Stem-Cell
Rights, N.Y. TIMES, Nov. 2, 2001, at C12.
141. See id.
142. See Victoria Griffith, Geron Moves to Settle Stem Cell Suit Marks Shift, FIN.
TIMES, available at
http://news.ft.com/ft/gx.cgi/ftc?pagename=View&c=Article&cid=FT3ZYZBOBW
C (Jan. 10, 2002); Yahoo! Finance, Geron Resolves Stem Cell Lawsuit with University, at
http://biz.yahoo.com/rf/020109/n09305338-l.html (last visited Jan. 9, 2002).
143. See Yahoo! Finance, supra note 143.
144. See Agreement, supra note 16.
145. See U.S. Patent No. 6,200,806 (issued Mar. 13, 2001).
146. Compare U.S. Patent No. 5,843,780 (issued Dec. 1, 1998), with U.S. Patent No.
6,200,806 (issued Mar. 13, 2001).
147. See U.S. Patent No. 6,200,806 (issued Mar. 13, 2001).
148. Shulman, supra note 2.
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has yet to be tested, but if the interpretation is correct, the '780
and '806 patents encompass the entire field of stem cell re-
search.'4 9 Thus, researchers in the United States will have to ob-
tain licenses from WiCell (a subsidiary of WARF) or its licensees
for any stem cell use. 5 0
WiCell announced in late 2001 that it had reached an
agreement to allow researchers to use stem cell lines for a low
fee.' 5' The use is restricted but allows ownership of any new in-
tellectual property that results from such research to be retained
by the researcher. 152
3. The Human Genome Project
What was once considered science fiction is readily becom-
ing a reality with the completion of the Human Genome Project
and President George W. Bush's policy to allow limited stem cell
research. 153 In 1996, scientists were able to clone a sheep, Dolly,
which is still alive and well. 5 4 Researchers mapped the human
genome in just over ten years.155 Research was accelerated in
1998 when Celera Genomics entered the sequencing race.1 56 The
completion of the genome sequence is the first step in under-
standing how humans grow, develop, and become ill.'57 The
next wave of research is proteomics,15 8 which seeks to under-
stand complete proteins-including how they interact and their
mechanisms.'5 9
This next step for research is more complicated because al-
though all cells are genetically the same, the same genes can
149. See id.
150. See id.
151. See Agreement, supra note 16.
152. See id.
153. See REGISTRY, supra note 9; Lemonick, supra note 1.
154. See Andy Coghlan & Claire Ainsworth, Don't Expect Any Miracles, NEW
SCIENTIST, Dec. 1, 2001, at 4.
155. See Eric S. Lander et al., Initial Sequencing and Analysis of the Human Genome,
NATURE, Feb. 15, 2001, at 860, available at
http://www.nature.com/genomics/human/papers/40986OaO fs l.html (describ-
ing the history of the Human Genome Project and the injection of the private sector
into the competition by the addition of Celera genomics, and commenting on the
difference in the approaches of the Human Genome Project and Celera leading to
the drafting of the sequence).
156. See id.
157. See id.
158. See Spotting Protein, supra note 126.
159. See Post-Genomic Challenge, supra note 107.
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"build a whole range of cellular machines." 160 Every individual
contains different specialized cells such as muscle, hair, and mi-
tochondria. These cells are differentiated from one another be-
cause only a specific segment of DNA is expressed in each cell
type.161 DNA expression ultimately leads to the production of a
set of proteins specialized for each cell type.162 These proteins
"fold into complex shapes, join[ing] forces to create molecular
machines and factories" 163 that carry out bodily functions.
64
Not everyone believes genetic alteration research should be
done. 65 Life on this planet is an ongoing evolutionary process
that is 3.5 billion years old;166 some experts believe the use of ge-
netically-altered organisms could result in ecological disaster.
67
For example, if a genetically altered organism were introduced
into the natural environment, there would be virtually no con-
trol over it.168 The simplest examples are "genes for disease or
herbicide resistance [that] could migrate from genetically-altered
crops into their weedy relatives, resulting in vigorous and diffi-
cult to control pests." 69 Once initiated, recalling these "genes"
is nearly impossible.'70
a. Potential Harm
Problems caused by the intentional and unintentional intro-
duction of exotics should humble us about our ability to pre-
dict and control the effects of our actions on ecosystems.
Even in cases where no adverse impacts on the ecological
functioning of natural ecosystems occur, the mere presence
of introduced genes and genetically-altered organisms de-
grades these ecosystems by diminishing the naturalness or
wildness of these ecosystems.' 71
160. Philip Cohen, High in Protein, NEW SCIENTIST, Nov. 4, 2000, at 38.
161. Peter Toilman et al., Evaluating the Costs: Pharmaceutical Research and Devel-
opment, CHEMICAL MARKET REP., July 30, 2001, at 19.
162. Id.
163. Id.
164. See Licking et al., supra note 130.
165. See P. R. Phifer & L. L. Wolfenbarger, The Ecological Risks and Benefits of Ge-
netically Engineered Plants, SCIENCE, Dec. 15, 2000, at 2088.
166. See id. (featuring Eric Alexander of MIT's Whitehead Center voicing con-
cerns over human germline therapy).
167. See Hettinger, supra note 20, at 299.
168. See id.
169. Id. at 300.
170. See id.
171. Id. (citations omitted).
[Vol. 43
STEM CELL RESEARCH & PATENTS
The "exotic" pharmaceuticals used to treat Acquired Im-
munodeficiency Syndrome (AIDS) are perfect examples of good
intentions throwing obstacles in the path of progress. Physi-
cians employed AZT as their drug of choice to treat AIDS in the
1980s.172 AZT lowered the viral load (amount of virus in the
body) but did not eradicate the virus.173 Soon, AZT began to
lose its effectiveness as the virus began to become resistant.174
Subsequently, scientists started mixing drug cocktails to combat
AIDS.175 While mutation of the virus has temporarily slowed,
today one out of every seven new HIV patients has a drug resis-
tant strain. 76 It is not uncommon for patients to take sixty pills
throughout the day.177 While drugs have prolonged the life of
infected patients, they have simultaneously done the virus a fa-
vor. By increasing the life of its host, the virus is provided with
more opportunities to spread by infecting other individuals.
Another example of unintended and unanticipated harm
has occurred in genetically modified crops. The European "corn
borer" is an insect that feeds on corn and costs American farm-
ers an estimated $1 billion in lost crops. 78 Bacillus thuringiensis,
a bacterium, produces a protein that kills certain crop-
destroying pests.179 Mycogen invented a genetically-modified
crop that produces high amounts of this protein, which dis-
solves the insect's stomach lining after ingestion and results in
the pest's death.1 80 Recent reports suggest that in addition to
killing the intended pest, the European corn borer, it also kills
unintended victims-Monarch butterfly larvae.' 8 ' Genetically al-
tered crops pose other harmful concerns; they can cause human
172. See Anne Bullers, Living with AIDS-20 Years Later, FDA CONSUMER, Nov. 1,




176. See Bruce Stokes, No Easy Cure, NAT'L J., Mar. 31, 2001, at 968 (opining that
patent protection provides the incentive for pharmaceutical companies to continue
developing drugs to combat AIDS).
177. See Licking et al., supra note 130; Hettinger, supra note 20.
178. See Mycogen Plant Sci., Inc. v. Monsanto Co., 243 F.3d 1316, 1321 (Fed. Cir.
2001) (providing background information on the invention at dispute in an appeal
brought forth by Mycogen challenging the decision of the District Court upholding




181. See Dan Ferber, GM Crops in the Cross Hairs, Controversy Continues over the
Safety of Genetically Modified Crops, SCIENCE, Nov. 26, 1999, at 1662.
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allergic reaction to transgenic foods,182 threaten beneficial insects
indirectly through the food chain,183 and cause pests in succes-
sive generations to be increasingly resistant to those crops.1
84
Genetically engineered organisms also present the risk of
being invasive to the ecosystem. 185 These species cost the United
States $137 billion annually.186 Viruses with new biological
characteristics may arise in genetically altered plants, but there
is currently a lack of empirical data available to determine the
degree of potential harm.187
b. Benefits
On the other hand, biotechnology and scientific advances
offer the potential of increasing the quality of human life.
188
Human germline therapy, would in theory, replace an individ-
ual's defective genetic trait and pass the correction onto one's
progeny. 189 James Watson, one of the scientists that discovered
the double helical structure of DNA, believes that the science of
the future has the capability of saving us.1 90 The American As-
sociation for the Advancement of Science (AAAS) has estimated
that 128 million Americans are utilizing the benefits of therapies
and treatments made possible from stem cell research.191 In
182. See id. ("[P]eople allergic to Brazil nuts are also allergic to soybeans that
have been engineered to express a Brazil nut to make them more nourishing.")
Upon this discovery, Pioneer Hi-Bred did not commercialize its soy line. See id.
183. See id. (referring to a study that showed Monarch larvae feeding on its sole
food source, milkweed leaves, near the genetically modified bacillus thuringiensis
plants were seven times more likely to die within two days in comparison to Mon-
arch larvae feeding in non-genetically modified bacillus thuringiensis fields).
184. See id.
185. See Phifer & Wolfenbarger, supra note 165 ("[Invasive species] have spread
widely in their nonnative ecosystems and caused unintended degradation of natu-
ral ecosystem functions and structure.").
186. See id.
187. See id.
188. See Coghlan & Ainsworth, supra note 154; Lander et al., supra note 155; Spot-
ting Protein, supra note 126.
189. See Christine Willgoos, FDA Regulation: An Answer to the Questions of Human
Cloning and Germline Gene Therapy, 27 AM. J.L. & MED. 101, 105 (2001). A healthy
gene is introduced to replace a defective one. See id. An individual will contain the
healthy gene. See id. The defective gene is not passed to subsequent offspring. See
id.
190. See Ralph Brave, Governing the Genome: Which Genetic Modifications Should Be
Encouraged and Mhich Outlawed? Deep Divisions Exists Even Among Ethical Scientists
and Informed Activists, NATION, Dec. 10, 2001, at 18 ("It's germline, if anything, that
one day will save us... from.., something like AIDS.") (quoting interview with
James Watson, Nobelist (June 2000)).
191. See CHAPMAN ET AL., supra note 19 (relying on a compilation of data from
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1999, Americans spent nearly $100 billion on diabetes treat-
ment.192 Research using stem cells could eventually lead to the
therapeutic treatment of diabetes. 193 Alzheimer's Disease, Park-
inson's Disease, immunodeficiency diseases, and diseases of the




On July 31, 2001, the House of Representatives passed
House Resolution 2505,195 referred to as the Human Cloning
Prohibition Act of 2001, by a vote of 265 to 162.196 This Act bans
the creation of cloned human embryos for any purpose, includ-
ing creating embryonic stem cells for therapeutic and/or re-
search purposes.197 The House measure reads in pertinent part:
SEC. 302. PROHIBITION ON HUMAN CLONING
(a) In General. It shall be unlawful for any person or entity,
public or private, in or affecting interstate commerce, know-
ingly - -
(1) to perform or attempt to perform human cloning;
(2) to participate in an attempt to perform human cloning; or
(3) to ship or receive for any purpose an embryo produced
by human cloning or any product derived from such em-
bryo.
(b) Importation. It shall be unlawful for any person or entity,
public or private, knowingly to import for any purpose an
embryo produced by human cloning, or any product derived
from such embryo. 198
the Alliance for Aging Research, Washington D.C.).
192. See id.
193. See id. at 5 ("[Sitem cells, instructed to differentiate into a particular pancre-
atic cell called a beta cell, could overcome the shortage of therapeutically effective
material to transplant. They also afford the opportunity to engineer such cells to
effectively resist immune attack as well as graft rejection.").
194. See id.
195. See H.R. 2505, 107th Cong. (2001). If enacted, the act would amend Title 18
to prohibit all sorts of cloning, including, reproductive, therapeutic, and somatic.
See id.
196. See id. See also Munro, supra note 20.
197. See H.R. 2505, 107th Cong. § 302 (2001).
198. See id.
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In facing this Resolution, Congress is divided as to how to
address this issue.199 As of January 2002, the Senate had yet to
take up the issue.200 The Senate Majority Leader prevented Sen-
ate Resolution 790,201 which is nearly identical to House Resolu-
tion 2505, coming to the Senate floor until spring 2002.202
III. PROBLEM
Stem cell research, while currently in its infancy and years
away from providing beneficial technologies to the market-
place,203 presents several areas of genuine concern.
First is the issue of ownership. 204 Who will reap the re-
wards of the research? Will the donor of the stem cells leading
to developments and inventions have any ownership interest in
The term 'human cloning' means human asexual reproduction, accom-
plished by introducing nuclear material from one or more human somatic
cells into a fertilized or unfertilized oocyte whose nuclear material has
been removed or inactivated so as to produce a living organism (at any
stage of development) that is genetically virtually identical to an existing
or previously existing human organism.
Id. § 301(1). Asexual reproduction is "reproduction not initiated by the union of
oocyte and sperm." Id. § 301(2). A somatic cell is a "diploid cell (having a complete
set of chromosomes) obtained or derived from a living or deceased human body at
any stage of development." Id. § 301(3).
199. See Wesley J. Smith, Closing in on Cloning, WKLY. STANDARD, Jan. 14, 2002,
at 22 (arguing that cloning should be banned). See also John Miller & Ramesh Pon-
nuru, The Senate Punts on Cloning, NAT'L REV. ONLINE, at
http://www.nationalreview.com/daily/nr110l.shtml (Nov. 1, 2001) (comment-
ing that Republican Senator Brownback is against all forms of cloning while Repub-
lican Senator Specter is in favor of embryo research).
200. See Jennifer Hickey, Partisanship Rears Ugly Head, INSIGHT ON THE NEWS,
Dec. 24, 2001, at 10 (discussing Senate Majority Leader's announcement that he will
allow a vote on a six month ban of human cloning).
201. See S. Res. 790, 107th Cong. § 301 (2001) ("The term 'human cloning' means
human asexual reproduction, accomplished by introducing the nuclear material of
a human somatic cell into a fertilized or unfertilized oocyte whose nucleus has been
removed or inactivated to produce a living organism... with a human or pre-
dominantly human genetic constitution."). See also id. § 302.
It shall be unlawful for any person or entity, public or private, in or affect-
ing interstate commerce to -
(1) to perform or attempt to perform human cloning;
(2) to participate in an attempt to perform human cloning; or
(3) to ship or receive the product of human cloning for any purpose.
Id.
202. See id.
203. See Capell et al., supra note 7.
204. See Moore v. Regents of the Univ. of Cal., 51 Cal. 3d 120 (1990) (holding that
a patient has no property interest in his own cells excised during a medical proce-
dure even though the physician used it for his own financial gain).
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them or be able to share in their financial benefits?205
Second, are future inventions consisting of human organic
material such as cells, body parts, and perhaps genetically al-
tered human beings patentable under the existing statutes and
case law?20 6 Finally, are the patent statutes, as they exist now,
antiquated and ill-equipped to deal with the advances of future
technological innovation, such that they may run counter to the




The courts have been reluctant to find ownership interests
in individual biological material.208 There is no federal law con-
cerning the ownership interest of one's own biological material
when used for research purposes.209 Thus, when disputes arise,
205. See PROJECTIONS, supra note 21. By 2008, national expenditures on health
care are projected to be $2.3 trillion. See id.
206. See generally 35 U.S.C. § 101 (2001) (covering the eligible subject matter for
patentability); Diamond v. Chakarabarty, 447 U.S. 303 (1980) (deciding that the
proper question is not whether an organism is alive but whether it is a product of
nature); In re Bergy, 563 F.2d 1031 (C.C.P.A. 1977), vacated, 438 U.S. 902 (1978) (hold-
ing that a bacteria not existing in nature in pure form but only under carefully con-
trolled laboratory conditions was patentable).
207. See U.S. CONST. art. I, § 8, cl. 8. The Atomic Energy Act of 1954 removes
any nuclear or atomic energy invention from the protection of 35 U.S.C. § 101 if it is
primarily to be used as a weapon. See 42 U.S.C. § 2181(a) (2001). In its legislative
history, Congress recognized that "this legislation will speed atomic progress and
will promote the security and well-being of the nation." S. REP. No. 83-1699, at 5
(1954). Congress further noted:
We of this generation have been visited with a new form of energy which
can ravage this planet beyond recognition, or make it fair beyond the
wildest dream of our fathers. It is the hope, it is the prayer of those of us
who now commend this legislation to the Congress that the atom will not
be the destroyer but the server of humanity.
Id.
208. See Moore, 51 Cal. 3d. at 120; Davis v. Davis, 842 S.W.2d 588 (Tenn. 1992).
209. See Cain, supra note 26 (discussing the treatment of human biological mate-
rials by various states as a limited property issue); Hettinger, supra note 20 (discuss-
ing property rights on the basis of several theories: natural entitlement to fruits of
labor, market value, and biocentrism-which do not involve federal law, but address
states' handling of the matter); Sheila R. Kirschenbaum, Banking on Discord: Property
Conflicts in the Transplantation of Umbilical Cord Stem Cells, 39 ARIZ. L. REV. 1391
(1997) (discussing only the states' treatment on umbilical cord stem cells as prop-
erty concerns).
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state law has been used to decide the outcome of the cases.210
What is more perplexing is that in two of the most germane
ownership cases, the highest state courts decided the issue with-
out using property law.211
In Moore v. Regents of the University of California, the Su-
preme Court of California found that Moore no longer retained
any interest in his excised cells after a medical procedure pursu-
ant to California's Health and Safety Code.212 The Code limits
the continuing interest of a patient in his excised cells, and the
court noted that Moore did not expect to retain possession fol-
lowing his spleenectomy.21 3 The Moore court decided the case on
too narrow of an issue, disregarding the fact that Dr. Golde had
not fully informed Moore that his spleen cells were unique and
that he may have a financial interest in the research that was to
take place.214 Moore signed the written consent form without
being fully informed.215 The court recognized this stating that
"[i]ndeed, the law already recognizes that a reasonable patient
would want to know whether a physician has an economic in-
terest that might affect the physician's professional judg-
ment."216 Recognizing this about the procedure, the court's con-
clusion that Moore no longer had an interest in the excised cells
after the operation seems illogical. The court found that Golde
informed Moore "that he had reason to fear for his life, and that
the proposed splenectomy operation.., was necessary to slow
down the progress of his disease."217 Informed consent would
have given Moore the opportunity to seek a second medical
opinion on spleen removal, having knowledge of Golde's finan-
cial interest, and would provide a reason to maintain an interest
in his own cells post-operation. The court's deference to Cali-
fornia's Health and Safety Code is generally sound, because in
most instances a medical procedure is performed and cells are
excised with either fully informed consent and/or no further
210. See Moore, 51 Cal. 3d at 120 (applying California Health and Safety Code);
Davis, 842 S.W.2d at 588 (creating a quasi-property interest for the limited scope of
deciding the issue of discarding frozen embryos).
211. See Moore, 51 Cal. 3d at 120; Davis, 842 S.W.2d at 588.
212. See Moore, 51 Cal. 3d at 137.
213. See id.
214. See id. at 126. Prior to the spleenectomy, Golde and his colleague decided to
make use of Moore's spleen for commercial research purposes. See id.
215. See id.
216. Id. at 129.
217. Id. at 126.
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economic interests at stake beyond the procedure. 218 However,
in those rare situations where there is an economic interest at
stake and no informed consent, a patient should be allowed an
ownership interest in inventions derived from his excised cells.
In Davis v. Davis, the Supreme Court of Tennessee found
that Mr. Davis had a very limited quasi-property interest as to
whether unused frozen embryos should be discarded irrespec-
tive of his ex-wife's desire to donate them to a childless cou-
ple.219 Like Moore, Davis was a case of first impression and was
not decided on property law principles.220
As they pertain to stem cell research, inventions obtaining
funding from the NIH's $23 billion budget 221 must choose stem
cell lines with embryo donation received through informed con-
sent.222 Presumably, informed consent would resolve ownership
issues between the donor and the researchers for all research re-
ceiving NIH funding.223
However, the NIH's criteria only applies to researchers
seeking federal funding.224 Nothing prevents researchers with
private backing from obtaining stem cell lines developed from
embryos obtained outside the criteria of NIH guidelines.225 Pru-
dent private companies should make sure no ownership dis-
putes exist by utilizing both informed consent and entering into
contracts with donors. In the future, however, there could be
rare instances in which a physician or researcher could fail to
disclose his economic interest in the donor's embryo. Current
protocol of informed consent and contractual arrangements ap-
pears to resolve most ownership disputes. Nevertheless, prob-
lems arise when such arrangements are not implemented, lead-
218. See Moore, 51 Cal. 3d at 125.
219. See Davis, 842 S.W.2d at 590.
220. See id.
221. See National Institutes of Health, supra note 8.
222. See National Institutes of Health, Notice of Criteria for Federal Funding of Re-
search on Existing Human Embryonic Stem Cells and Establishment of NIH Human Em-
bryonic Stem Cell Registry, available at http://grants.nih.gov/grants/ guide/notice-
files/NOT-OD-02-005.html (Nov. 7, 2001) [hereinafter NIH Notice].
223. The donor will either have waived any interest, sold the embryos to the re-
searchers, or entered into a contractual relationship where the donor would receive
a financial return to be later determined. This conclusion is an amalgam of the ar-
gument offered in Pennisi, supra note 38.
224. See NIH Notice, supra note 222; Nicholas Wade, Scientists Divided on Limit of
Federal Stem Cell Money, N.Y. TIMES, Aug. 16, 2001, at A16 ("[P]rivate companies
have always been free to work on human embryonic stem cells").
225. See REGISTRY, supra note 9.
20031
SANTA CLARA LAWREVIEW
ing to cases such as Moore.226 These cases signal to the research
community that when in doubt as to whether informed consent
allows access to human cells for commercial exploitation, it is
better not to inform the patient and remove the material needed
because the courts seem to find in the researcher's favor.227
Thus, the lack of a regulatory regime encourages non-disclosure,
particularly considering that current stem cell lines are not suffi-
cient to meet research spanning the genetic diversity of our
population. 228 In such cases, when an individual has rare cells, it
may be particularly tempting not to disclose.
B. Patents
The goal of patent law is to promote the progress of the sci-
ences and useful arts.229 The patent statutes permit an inventor
to secure for a limited time, the right to exclude others from
making, using, or selling the patented invention.230 Therefore,
patents merely provide the patent owner the right to exclude
others231 and do not necessarily give the patent owner the right
to make, use, or sell his invention. 232 For example, one may have
a patent to a pharmaceutical drug, including the right to exclude
others. However, until the patent owner applies for FDA ap-
proval, he will not be allowed to sell the drug in the United
States.
Subject matter eligible for patenting must fall into one of
four categories. 233 Section 101 is silent as to whether living or-
ganisms are included as eligible subject matter.2 34 The Supreme
Court has answered this question in the affirmative.235 In Chak-
rabarty, the Supreme Court found that a type of oil-eating bacte-
226. See Moore v. Regents of the Univ. of Cal., 51 Cal. 3d 120, 120 (1990).
227. See id.
228. See Nicole Dyer, Stem Cells: The Next Cure?, SC. WORLD, Nov. 12, 2001, at 14
(stem cell lines necessary to meet our research needs are not currently available).
229. See U.S. CONST. art. I, § 8, cl. 8.
230. See 35 U.S.C. § 154(a)(2) (2001) ("Subject to the payment of fees under this
title, such grant shall be for a term beginning on the date on which the patent issues
and ending 20 years from the date on which the application for the patent was filed
in the United States .... ").
231. See CHISUM ET AL., supra note 85, at 3.
232. See id.
233. See 35 U.S.C. § 101 (2001).
234. See id.
235. See Diamond v. Chakrabarty, 447 U.S. 303 (1980) (holding that a non-
naturally occurring organism constitutes eligible subject matter because it is not a
product of nature); In re Bergy, 563 F.2d 1031 (C.C.P.A. 1977), vacated, 438 U.S. 902
(1978).
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ria, although a living organism, fell into eligible subject matter
because it was not a "product of nature."236 The Court found
that the oil-eating bacteria was a creation of scientific laboratory
engineering, making it non-naturally occurring and, therefore,
not a product of nature.
The dissent in Chakrabarty adopted the government's argu-
ment that Congress intended living things to be excluded from
the protection of 35 U.S.C. § 101, as evidenced by the enactment
of the PPA and the PVPA.237 The majority rejected this notion
and held that the Court could decide whether living organisms
are eligible subject matter under § 101.238 It is equally true that
once Congress has spoken, it is "'the province and duty of the
judiciary to say what the law is."'239
Recently, the Court in Pioneer International, using stronger
language, ruled that the PPA and PVPA do not preclude a plant
from being eligible subject matter under § 101.240 This time
around, the Court soundly rejected the notion that plants were
intended to be taken out of patentable subject matter, pointing to
the fact that the government could not find anyplace in the PPA
indicating that the Act would serve as the only means of intellec-
tual property protection for plants.241 As the Chakrabarty Court
firmly stated, "Congress has performed its constitutional role in
defining patentable subject matter in § 101; we perform ours in
construing the language Congress has employed." 242 Therefore,
even if Congress were to enact an act addressing intellectual
property protection for human organic matter, short of a con-
gressional amendment to 35 U.S.C. § 101, the Supreme Court,
consistent with the decision of Chakrabarty, would most likely
find that such materials would still fall within the protection of §
101.
Due to the lack of available technology, courts have not de-
cided whether human beings themselves or human cells arising
from stem cell research can be patented. However, stem cell re-
search is likely patentable when solely considering current statu-
tory code and case law.
236. See Chakrabarty, 447 U.S. at 306.
237. See id. at 320.
238. See id. at 315.
239. Id. (quoting Marbury v. Madison, 5 U.S. 137, 177 (1803)).
240. J.E.M. AG Supply, Inc. v. Pioneer Hi-Bred Int'l, Inc., 534 U.S. 124 (2001).
241. See id. at 134.
242. Chakrabarty, 447 U.S. at 315 (quoting Marbury v. Madison, 5 U.S. 137, 177
(1803)).
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C. Ramifications of the '780 and '806 Patents
The '780 patent provides patent protection to the owner of
the process and method of creating primate embryonic stem
cells.243 The '806 patent is a divisional application sharing a
written description with the '780 patent but having different
claims.244 All human embryonic stem cell research in the United
States falls under either the '780 or '806 patent,245 and thus needs
to be licensed by WiCell to avoid infringement by the researcher.
Generally, these broad patents could delay progressive research
in this field, but the NIH has an agreement with WiCell that al-
lows NIH researchers access to the stem cell lines for a reason-
able fee for educational and non-commercial research purposes
only. 246 Under the agreement, researchers may keep any intel-
lectual property resulting from the research, but would have to
obtain a separate commercial license from WiCell in order to
commercially exploit it.247
The '806 patent is very broad in scope.248 Critics argue that
patents on embryonic stem cells are totipotent or "so broad and
undifferentiated they can be seen to apply to virtually any re-
search problem in a given area." 249 However, WiCell's willing-
ness to license the patents should ease these fears.
The ability to make use of the stem cells for therapeutic
cloning is closely tied to the science of proteomics. Scientists
currently do not even know how to trigger the cellular mecha-
nism that causes stem cells to differentiate into specific cells
(e.g., human nerve cells) much less understanding how to direct
them to become specific organs. 250 It will be decades before pro-
teomics reveals such mechanisms. 251 It is a more daunting task
243. See U.S. Patent No. 5,843,780 (issued Dec. 1, 1998).
244. See U.S. Patent No. 6,200,806 (issued Mar. 13, 2001). See also U.S. Patent No.
5,843,780 (issued Dec. 1, 1998).
245. See Seth Shulman, supra note 2, at 33.
246. See Agreement, supra note 16. A fee of $5,000 is charged to cover the cost of
preparing the lines and shipping expenses. See id.
247. See National Institutes of Health, Memorandum of Understanding Between
WiCell Research Institute Inc. and Public Health Services and United States Department of
Health and Human Services, available at
http://www.nih.gov/news/stemcell/WicellMOU.pdf (last visited Sept. 24, 2001).
248. See U.S. Patent 6,200,806 (issued Mar. 13, 2001) (claiming all human embry-
onic stem cells and the method of preparing them).
249. Shulman, supra note 2.
250. See id.
251. See Capell et al., supra note 7 (discussing that proteomics is just underway
and the lack of a quick analytical tools such as the microarray that was used for se-
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than the Human Genome Project, and by the time scientists un-
derstand how proteins interact in triggering cellular mecha-
nisms sufficiently, the Thomson patents will have expired. In
the grand scheme of the state of proteomics, the Thomson Pat-
ents, while broad, do not have wide reaching effects because the
path of progress is slow in this field.
D. The Danger that New Technology May Bring
Congress has once before prohibited certain technologies
from gaining patent protection. In 1954, Congress recognized
the potential devastation that nuclear and atomic technology
poses, commenting, "we of this generation have been visited
with a new form of energy which can ravage this planet beyond
recognition." 252 Addressing this concern, Congress enacted a
statute prohibiting the patenting of nuclear or atomic inventions
primarily intended for use as weapons.25 3 However, Congress
also recognized the benefits of riuclear technology, as evidenced
by the fact that the Atomic Energy Act of, 1954 did not ban all
nuclear or atomic inventions from patent protection. 254 While the
Thomson patents may not have as great of an effect as some give
them credit for,255 the patent statutes, as they stand, can be very
dangerous to society in general.
Current law permits patenting of virtually any invention,
including human beings and human matter.256 However, we are
just beginning to understand the effects of proteomic research. 257
In the United States, genetically-modified organisms cost $137
billion annually.258 The lack of understanding has the potential
of creating greater harm to society and the ecosystem, 259 much
like the harm nuclear and atomic inventions threatened in the
past. Scientists likely have good intentions behind their re-
search, but are faced with a large market and a relatively infan-
quencing the genome means it will take decades before any meaningful under-
standing can be had).
252. S. REP. No. 83-1699, at 9 (1954).
253. See 42 U.S.C. § 2181(a) (2001) (prohibiting the patenting of nuclear or atomic
inventions primarily developed as weapons but permitting the patenting of those
nuclear or atomic inventions whose primary purpose is not to be a weapon).
254. See id.
255. See Capell et al., supra note 7.
256. See Diamond v. Chakrabarty, 447 U.S. 303, 303 (1980).
257. See Cohen, supra note 160.
258. See Phifer & Wolfenbarger, supra note 165.
259. See supra notes 165-87 and accompanying text.
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tile understanding of the human genome; therefore, their geneti-
cally-altered inventions related to therapeutic cloning could
prove disastrous to humankind.260
V. PROPOSAL
Patents offer a great incentive to spur on scientific progress.
Science is in its infancy in understanding the inner workings of
genetic and cellular mechanisms. 261 This lack of understanding
makes unintended harm more likely. This unintended harm has
already occurred in genetically altered plants, where unintended
targets are being killed 262 and human life is put at risk due to al-
lergic reactions. 263 Therefore, Congress is rightly concerned. 264
However, House Resolution 2505 is over-inclusive, and if en-
acted, would ban both human reproductive cloning and thera-
peutic cloning.265
An overwhelming majority of researchers and private com-
panies abide by the proper protocol whereby ownership is re-
solved.266 However, recent judicial decisions refusing to grant
donors appreciable ownership 267 encourage physicians to decep-
tively obtain donor cells when faced with the billions of dollars
at stake.
In order to solve the questions of ownership for intellectual
property arising from uninformed consent,268 tissue donors
should be able to retain a fractional ownership interest in their
cells and be able to share in the financial return resulting from
the use of the cells. Congress should enact laws permitting do-
nors to retain an ownership interest in their tissues, even when
they are not fully informed of the financial stakes. The main fo-
cus of these efforts should be on updating antiquated patent
laws, enacted when such scientific marvel was but a fantasy.
Such laws would provide the necessary incentive for doctors
260. See Moore v. Regents of the Univ. of Cal., 51 Cal. 3d 120, 120 (1990). Moore
was not fully informed, specifically of his physician's financial interest, yet the
court held he had no property interests in his excised cells. See id. at 126.
261. See Post-Genomic Challenge, supra note 107.
262. See Ferber, supra note 181.
263. See id.
264. See Munro, supra note 20 (referring to the House passing a measure to ban
all forms of human cloning by a vote of 265 to 162).
265. See id.
266. See Moore v. Regents of the Univ. of Cal., 51 Cal. 3d 120, 125 (1990); Davis v.
Davis, 842 S.W.2d 588 (Tenn. 1992).
267. See Moore, 51 Cal. 3d at 125; Davis, 842 S.W.2d at 588.
268. See id.
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and researchers to follow proper protocol, or risk sharing the re-
sulting revenue.
A commission comprised of scientists and ethicists should
be established to study the issues and formulate a proposal to
exclude certain therapeutic cloning from patent protection.
Upon the commission's recommendation, Congress should pass
an act similar in effect to 42 U.S.C. § 2181 (a): prohibiting harmful
technology from gaining patent protection, but permitting pro-
tection for beneficial technology. 269 While it will not eviscerate
any chance of harm, removing patent protection for some tech-
nologies would greatly slow progress in categorically harmful
therapeutic cloning by taking away the financial incentive asso-
ciated with ownership.
VI. CONCLUSION
Stem cell research promises a future of miracles. Diseases
once incurable are now cured and medical ailments resulting
from aging or bad luck are reversed. 270 What was once science-
fiction marvel is now approaching realization. Yet, the potential
for human peril may never have been greater. The science of
manipulation of stem cells for therapeutic purposes is far from
attaining a state of mastery over the body's complex mecha-
nisms.271 History provides ample lessons of benign motives
yielding unintended malignant environmental and economic
consequences. 272 This time, the stake may be humanity itself.
The current statutory regime encourages physicians to de-
ceive patient donors by rewarding doctors financially for their
exploits but depriving the patient donor of any financial stake.
Simply giving exploited patients a financial interest will provide
an incentive for physicians and researches to follow proper pro-
tocol or face the risk of reduced (or entirely eliminated) revenues
if the product becomes commercially viable. The patent statutes,
remaining true to their 1952 enactment, are ill equipped to deal
269. See 42 U.S.C. § 2181(a) (2001).
270. See Sheryl G. Stolberg, supra note 11, at Al.
Stem cells, the human body's master cells, can grow into any one of the
body's more than 200 cell types, and scientists hope to use them to create
replacement tissue and body parts. Advocatees for patients see the cells as
their best hope for treating a range of disorders, from Parkinson's disease
to juvenile diabetes.
Id.
271. See Capell et al., supra note 7, at 20.
272. See supra Part II.C.3.a.
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with the future scientific advances of the twenty-first century.
Much harm can be done because little is known. A preemptive
strike disallowing certain types of therapeutic cloning is a bal-
anced approach that stays true to the intent of patent law 273
while recognizing that certain activity is so dangerous to hu-
mans and the ecosystem274 that it should not be protected.
273. See U.S. CONST. art. I, § 8, cl. 8 ("To promote the Progress of Science and
useful Arts, by securing for limited Times the to Authors and Inventors the exclu-
sive Right to their respective Writings and Discoveries.").
274. See S. REP. No. 83-1699, at 9 (1954) (relating to 42 U.S.C. § 2181(a) (2000),
which permits the patenting of beneficial nuclear or atomic inventions but prohibit-
ing the patent protection of nuclear or atomic invention serving primarily as weap-
ons, noting that they could ravage the earth).
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